Association Between Hormone Therapy and Muscle Mass in Postmenopausal Women

Javed, Ayesha A.; Mayhew, Alexandra; Shea, Alison K.; Raina, Parminder

doi:10.1001/jamanetworkopen.2019.10154

Cited by 65 publications

(48 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because the between‐group differences in changes in FFM were not statistically significant, the effect of the exercise intervention must be interpreted cautiously and should be confirmed. Interestingly, a recent systemic review and meta‐analysis found no beneficial effect of hormone therapy on muscle mass retention in postmenopausal women (38). This emphasizes the need to more thoroughly understand the role of estrogen in maintenance of FFM in women and to develop strategies for preventing loss in aging women.…”

Section: Discussionmentioning

confidence: 99%

A Randomized Controlled Trial of Ovarian Suppression in Premenopausal Women: No Change in Free‐Living Energy Expenditure

Gavin

Melanson

Hildreth

et al. 2020

Obesity

View full text Add to dashboard Cite

Objective The purpose of this study was to determine whether suppression of ovarian function (gonadotropin‐releasing hormone agonist [GnRHAG]) for 24 weeks in premenopausal women approaching menopause causes changes in body composition and a decline in free‐living physical activity energy expenditure (PAEE) and whether endurance exercise training attenuates the changes. Methods Premenopausal women who were approaching menopause (mean [SD]: age 46 [3] years, BMI 26.3 [4.8] kg/m2) were randomized to 24 weeks of GnRHAG (n = 14), GnRHAG + Exercise (n = 11), or placebo (n = 9). Endurance exercise was performed 4 days per week with the goal of expending 200 to 300 kcal per session. Primary outcome measurements included body composition by dual‐energy x‐ray absorptiometry, total daily energy expenditure (TDEE), and PAEE by doubly labeled water, and resting energy expenditure (REE) by indirect calorimetry. Results Changes in TDEE, PAEE, REE, or body composition were not different between groups. However, within the GnRHAG group, fat mass increased (mean [SE]: total 1.7 [0.4] kg, trunk 0.9 [0.2] kg, leg 0.6 [0.2] kg) and fat‐free leg mass decreased (mean [SE]: −0.4 [0.2] kg) significantly. Conclusions In premenopausal women approaching menopause, ovarian hormone suppression resulted in increased adiposity without alterations in TDEE, PAEE, or REE.

show abstract

Section: Discussionmentioning

confidence: 99%

A Randomized Controlled Trial of Ovarian Suppression in Premenopausal Women: No Change in Free‐Living Energy Expenditure

Gavin

Melanson

Hildreth

et al. 2020

Obesity

View full text Add to dashboard Cite

show abstract

“…The potential contribution of CSA/periodic breathing on decline in heart function and outcomes motivated clinicians and researchers to delineate optimal treatment strategies. Therapeutic goals include improvement in cardiac function, reduction of hospitalisations, morbidity and mortality and, if these are not possible, enhancement of quality of life (QoL) [22].…”

Section: Challenges In Managing Csa/periodic Breathing In Chf With Rementioning

confidence: 99%

“…However, the study results have been challenged owing to a high percentage (23%) of the study population switching from control to ASV or vice versa, low ASV adherence (40% of patients used the ASV device <3 h per day, 26.7% 0 h per day) and unbalanced use of antiarrhythmic drugs between the two arms [45,46]. Post hoc analyses showed that ASV negative impact was mainly restricted to patients with the lowest LVEF (<30%) and those with the highest proportion of periodic breathing [22,47]. Therefore, the contraindications of ASV should not been extended to the CHF population with preserved ejection fraction and/or to HFrEF >45%.…”

Section: Challenges In Managing Csa/periodic Breathing In Chf With Rementioning

confidence: 99%

Central sleep apnoea and periodic breathing in heart failure: prognostic significance and treatment options

et al. 2019

View full text Add to dashboard Cite

Central sleep apnoea (CSA) including periodic breathing is prevalent in more than one-third of patients with heart failure and is highly and independently associated with poor outcomes. Optimal treatment is still debated and well-conducted studies regarding efficacy and impact on outcomes of available treatment options are limited, particularly in cardiac failure with preserved ejection fraction. While continuous positive airway pressure and oxygen reduce breathing disturbances by 50%, adaptive servoventilation (ASV) normalises breathing disturbances by to controlling the underlying mechanism of CSA. Results are contradictory regarding impact of ASV on hard outcomes. Cohorts and registry studies show survival improvement under ASV, while secondary analyses of the large SERVE-HF randomised trial showed an excess mortality in cardiac failure with reduced ejection fraction. The current priority is to understand which phenotypes of cardiac failure patients may benefit from treatment guiding individualised and personalised management.

show abstract

“…However, several limitations, such as the inclusion of studies with low-quality evidence, lack of information on the impact of different regimens (i.e., cyclical vs. continuous HRT, amount of physical activity, and ethnicity), need to be acknowledged. 101 Conversely, a more recent study of 4,254 Korean women showed that prolonged use of HRT was associated with higher muscle mass and lower prevalence of sarcopenia in postmenopausal women with more pronounced effects in younger and leaner women. 102 However, data examining the effect of estrogen replacement on muscle endpoints in POI is scarce, with one study in adult women with TS showing an increase in LBM with higher doses of oestradiol.…”

Section: Estrogen Replacement and Other Hormonal Therapiesmentioning

confidence: 96%

Musculoskeletal Health in Premature Ovarian Insufficiency. Part One: Muscle

et al. 2020

View full text Add to dashboard Cite

Accelerated bone loss and muscle decline coexist in women with premature ovarian insufficiency (POI), but there are significant gaps in our understanding of musculoskeletal health in POI. This article is the first of a two-part review which describes estrogen signaling in muscle and its role in musculoskeletal health and disease. Current evidence regarding the utility of available diagnostic tests and therapeutic options is also discussed. A literature review from January 2000 to March 2020 was conducted to identify relevant studies. Women with POI experience significant deterioration in musculoskeletal health due to the loss of protective effects of estrogen. In addition to bone loss, muscle decay and dysfunction is now increasingly recognized. Nevertheless, there is a paucity of validated tools to assess muscle parameters. There is a growing need to acknowledge bone–muscle codependence to design new therapies which target both muscle and bone, resulting in improved physical performance and reduced morbidity and mortality. More high-quality research and international collaborations are needed to address the deficiencies in our understanding and management of musculoskeletal health in women with POI.

show abstract

Association Between Hormone Therapy and Muscle Mass in Postmenopausal Women

Cited by 65 publications

References 70 publications

A Randomized Controlled Trial of Ovarian Suppression in Premenopausal Women: No Change in Free‐Living Energy Expenditure

A Randomized Controlled Trial of Ovarian Suppression in Premenopausal Women: No Change in Free‐Living Energy Expenditure

Central sleep apnoea and periodic breathing in heart failure: prognostic significance and treatment options

Musculoskeletal Health in Premature Ovarian Insufficiency. Part One: Muscle

Contact Info

Product

Resources

About